Tennessee has become the second state to pass a law allowing pharmaceutical companies to market their products for off-label uses; a House panel advanced legislation that would expand access to private sector care outside of the Veterans Affairs (VA) health system; and nearly half of oncologists recommend medical marijuana to their patients.
Tennessee has become the second state to pass a law allowing pharmaceutical companies to market their products for off-label uses, as long as the information given to doctors is accurate. The law goes into effect July 1 and comes amid rising pressure for the FDA to loosen regulations for off-label use, reported STAT News. Arizona became the first state to enact such legislation last March.Earlier this week, a House panel advanced legislation that would expand the number of veterans who are eligible to see private health specialists and would entitle veterans enrolled in the Veterans Affairs (VA) health system to see a private doctor twice a year without a co-pay, according to The Hill. The reform package, called the VA Mission Act, also includes $5.2 billion to keep the Veterans Choice Program funded until the implementation of the new system.A new survey of 237 oncologists nationwide found that approximately 80% discuss medical marijuana with their patients, NPR reported. Although less than 30% of them feel they have sufficient knowledge to advise them about medical use, nearly half do recommend medical marijuana for their patients. The survey also indicated that the majority of conversations about medical marijuana were initiated by the patient.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen